News
ELEV
3.820
-4.50%
-0.180
Elevation Oncology Shares Swing to 5% Gain After Extending Cash Runway
Elevation Oncology shares were up 5% to $4.14 in midday trading. The oncology company reported a wider-than-expected quarterly loss. The company raised enough cash through a stock facility to fund operations into 2026. The stock was down as much as 15% earlier in the day.
Dow Jones · 18h ago
ELEV Stock Earnings: Elevation Oncology Misses EPS for Q1 2024
Elevation Oncology reported earnings per share of -23 cents for the first quarter of 2024. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -20 cents. Elevation oncology also reported results for the fourth quarter of 2015.
Investorplace · 18h ago
Elevation Oncology files for $350M mixed shelf
Healthcare Elevation Oncology files for $350M mixed shelf May 02, 2024 1:27 p.m. Elevation oncology filed a prospectus for a mixed securities shelf offering of up to $350 million. The company is a subsidiary of Elevation Pharmaceuticals.
Seeking Alpha · 19h ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Emergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's, Q1 earnings came out yesterday. Nuwellis (NASDAQ:NUWE) and Sensei Biotherapeutics also moved upwards. Accuray and Metagenomi were among the losers.
Benzinga · 20h ago
Elevation Oncology Q1 2024 GAAP EPS $(0.23) Misses $(0.20) Estimate
Benzinga · 1d ago
Elevation Oncology GAAP EPS of -$0.23
Seeking Alpha · 1d ago
ELEVATION ONCOLOGY INC FILES FOR MIXED SHELF OF UPTO $350 MLN- SEC FILING
Reuters · 1d ago
ELEVATION ONCOLOGY INC: IN ADDITION, PROSPECTUS RELATES TO OFFER FROM TIME TO TIME UP TO 3.3 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS
Reuters · 1d ago
*Elevation Oncology Raised $44.2 M Yr-to-date Through ATM Facility, Extending Cash Runway Into 2026 >ELEV
Dow Jones · 1d ago
ELEVATION ONCOLOGY INC: RAISED $44.2 MLN YEAR-TO-DATE THROUGH ATM FACILITY, EXTENDING CASH RUNWAY INTO 2026
Reuters · 1d ago
ELEVATION: ENROLLMENT ONGOING IN PHASE 1 CLINICAL TRIAL OF EO-3021 IN U.S. AND JAPAN; EXPECT TO ANNOUNCE INITIAL SAFETY AND EFFICACY DATA BY MID-3Q
Reuters · 1d ago
Press Release: Elevation Oncology Reports First -2-
Income tax expense is a non-GAAP measure. Dow Jones & Company's net loss per share for the year ended March 31, 2024 is $0.72. The company's total assets and liabilities are less than the value of the common shares outstanding. The Company expects to have a net loss of $1.2 billion in the year ending May 30, 2024.
Dow Jones · 1d ago
Press Release: Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business achievements. Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. And Japan. Presented preclinical proof-of-concept data for HER3-ADC program at AACR Annual Meeting. Raised $44.2 million year-to-date through ATM facility, extending cash runway into 2026.
Dow Jones · 1d ago
*Elevation Oncology 1Q Loss/Shr 23c >ELEV
Dow Jones · 1d ago
Weekly Report: what happened at ELEV last week (0422-0426)?
Weekly Report · 4d ago
Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)
Elevation Oncology, Inc. Has had a successful year. Their flagship project, EO-3021, is a phase 1 study targeting Claudin-18.2 and has shown promising early results. The company is also exploring anti-HER3 ADCs and is close to nominating a candidate for clinical development. Elevation oncology is a small-cap biotech with a promising pipeline.
Seeking Alpha · 04/22 15:00
Weekly Report: what happened at ELEV last week (0415-0419)?
Weekly Report · 04/22 09:15
Weekly Report: what happened at ELEV last week (0408-0412)?
Weekly Report · 04/15 09:14
Elevation Oncology Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 04/09 10:31
HC Wainwright & Co. Reiterates Buy on Elevation Oncology, Maintains $6 Price Target
Benzinga · 04/09 10:21
More
Webull provides a variety of real-time ELEV stock news. You can receive the latest news about Elevation Oncolo through multiple platforms. This information may help you make smarter investment decisions.
About ELEV
Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.